Last reviewed · How we verify
Senna-S (SENNA)
At a glance
| Generic name | SENNA |
|---|---|
| Sponsor | HealthLife of USA LLC |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- constipation
Common side effects
Key clinical trials
- RELISTOR's Effects on Opioid-Induced Constipation
- Optimization of Postoperative Bowel Habits (NA)
- Whatsapp Based Patient Education to Improve Bowel Preparation for Colonoscopy (NA)
- The Effect of Video-Based Education on Colonoscopy Preparation (NA)
- Impact of the Inno Cleanse Dietary Supplement on Gut Health and Associated Variables in Healthy Men and Women (NA)
- Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma (PHASE2)
- PEG3350 vs Senna After Urogyn Surgery (PHASE4)
- Docusate/Senna for the Treatment of Diabetic Gastroparesis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Senna-S CI brief — competitive landscape report
- Senna-S updates RSS · CI watch RSS
- HealthLife of USA LLC portfolio CI